BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Musculoskeletal Transplant Foundation -- First Tissue Bank to Receive Approvals to Market Allografts in Australia


7/12/2013 9:33:10 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EDISON, N.J., July 11, 2013 /PRNewswire/ -- MTF, the Musculoskeletal Transplant Foundation, announced today that it is the first tissue bank to receive approvals to market human allografts in Australia under the new Australian Biologics Framework, implemented in May 2011.

The first two approved biologics in Australia are:

  • DBX® Putty - an osteoinductive bone allograft processed from donated human tissue, specifically designed to meet the Australian medical and regulatory requirements, and
  • FlexHD® and FlexHD® Pliable allografts processed from donated human skin and packaged in an ethanol solution.

According to Bruce Stroever, MTF President & Chief Executive Officer, "These were complicated, multi-year projects and we are delighted that our facilities, processes and people have met the Australian Therapeutic Goods Act requirements. Of special note, our new in-process bioburden testing method and isolator technology were critical in achieving approval of DBX® from the Australian authorities."

DBX®, a Demineralized Bone Matrix, is an allograft bone void filler used for the treatment of surgically created bone defects, or bone defects created from traumatic injuries. It can be used as a bone extender in orthopaedic, spine and trauma applications. DBX® has been approved for use in over 50 countries.

FlexHD® and FlexHD® Pliable are intended for use in the replacement of damaged or inadequate integumental tissue, or for the reinforcement or supplemental support of soft tissue defects. These allografts have been used extensively for hernia repair as well as for patients needing breast reconstruction following mastectomy.

Stroever noted that MTF's quality and safety standards now meet or exceed the requirements of the American Association of Tissue Banks (AATB), US Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA).

About MTF:
The Musculoskeletal Transplant Foundation (www.MTF.org), one of the nation's leading tissue bank, changes lives by connecting donors and transplant recipients. As a non-profit service organization, MTF is dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. Since our inception in 1987, MTF has received tissue from more than 100,000 donors and distributed more than 5.5 million-grafts for transplantation.

For information: Cindy Gordon, Issues Management LLC, 609-252-1300

SOURCE Musculoskeletal Transplant Foundation



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES